Buy or sell Metacrine stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Metacrine Stock

Metacrine is a privately held biotech company

Founded

2015

Notable Investors

ARCH Venture Partners

Headquarters

San Diego CA, US

Total Funding

$123M

About Metacrine Stock

Metacrine is a privately held biotech company 
founded in 2015 on technology licensed from the 
laboratory of Dr. Ronald Evans, a world leader in
 nuclear hormone receptors and Howard Hughes
Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

Investors

Funding History

August 2015$36.0M
December 2017$22.0M
June 2018$65.0M

Management

CEO

Neil McDonnell

CFO

Trisha Millican

CEO & President

Ken Song

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Metacrine or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 130K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo